The patients were injected with Avastin, a treatment for macular degeneration. A study published in the New England Journal of Medicine this year showed Avastin is a cost-effective alternative to Lucentis, an FDA-approved treatment also for macular degeneration. However, Lucentis costs approximately $2,000, compared to $50 for Avastin, which is not available in single-dose vials, according to the report.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Avastin is not FDA-approved due to that reason, forcing hospital pharmacies to compound the drug for intravenous use, according to the report. Notably, sterility issues stemming from compounding drugs was the subject of a VA advisory bulletin posted in 2006, warning patients of eyeball inflammation due to Avastin injections.
Read the report about contaminated Avastin injections at Nashville VA Medical Center.
Related Articles on Quality:
Connecticut Surgery Center Shuttered Over License Suspension Set to Reopen
Two-Thirds of Illinois Surgery Centers Inspected Cited for Infection Control Problems
CMS Update Reveals Mortality Rates for Heart Failure, Pneumonia; 30-Day Readmission Rates for Heart Attack Slightly Up
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.